Overview

Phase II Open-Label Trial of Tacrolimus/Methotrexate and Tocilizumab for the Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Status:
Completed

Trial end date:
2018-09-01

Target enrollment:

Participant gender:

Summary

This is a phase II open label trial designed to evaluate the efficacy of Tac/MTX/Toc in preventing graft versus host disease (GVHD). Outcomes of patients on this clinical trial will be compared to those of contemporary controls from the CIBMTR.

Phase:

Phase 2

Details

Lead Sponsor:

William R. Drobyski, MD

Treatments:

Methotrexate
Tacrolimus